Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GSK2798745 in Diabetic Macular Edema
NCT04292912Phase 1Terminated
- Sponsor
- GSK
- Start
- Sep 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of GSK2798745 in diabetic macular edema (DME), sponsored by GSK. Primary endpoints: Number of Participants With Abnormal Ophthalmic Examination Findings, Mean Change From Baseline to Day 28 in Visual Acuity and 5 more. Started Sep 2020; status: terminated.
02
Drugs
GSK2798745
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04292912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04292912.